NEW YORK (GenomeWeb) – CRISPR-based therapy developer Editas Medicine is looking to raise up to $122 million in a planned initial public offering, according to an amended prospectus filed today with the US Securities and Exchange Commission.

According to the amended Form S-1, Editas has registered to sell 5.9 million shares with a proposed price per share between $16 and $18, for a maximum offering price just over $122 million. The firm will also offer 885,000 shares of common stock to the underwriters to cover over-allotments.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York City medical examiner is overseeing an effort to identify missing persons using DNA, according to the Associated Press.

Nobel laureate Günter Blobel has died at 81, the New York Times reports.

In PNAS this week: mouse model of genetically induced emphysema, gene expression signatures of circulating melanoma cells, and more.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

Mar
08
Sponsored by
Swift Biosciences

This webinar will discuss an optimized protocol for methyl-CpG binding domain sequencing (MBD-seq), which enables comprehensive, adequately powered, and cost-effective large-scale methylome-wide association studies (MWAS) of almost all 28 million CpG sites in the genome.

Apr
03
Sponsored by
Dovetail Genomics

Proximity ligation technology generates multi-dimensional next-generation sequencing data that is proving to solve unmet needs in genomic research. 

Apr
05
Sponsored by
Labcyte

This webinar will discuss how acoustic liquid handling can reduce the time and costs for labs performing carrier screening with next-generation sequencing.